Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Medtronic’s Resolute Integrity tops Abbott’s Xience | ACC 2016 roundup
Results from the Propel all-comers trial comparing Medtronic‘s Resolute Integrity drug-eluting stent showed it to be superior to the Xience stent made by rival Abbott. Read more
4. Penumbra launches Lantern peripheral microcatheter
Penumbra said it launched its Lantern peripheral microcatheter and reported Phase IV data from a 100-patient trial of its Indigo peripheral thrombectomy device.
The Lantern device won 510(k) clearance from the FDA in December 2015 for the peripheral and neurovascular delivery of diagnostic agents and therapeutic devices such as occlusion coils. YY-based Penumbra makes the Ruby coil, Penumbra occlusion device and its packing coil. Read more
3. ResMed closes $800m Brightree buy
ResMed said it closed the $800 million acquisition of cloud-based healthcare software company Brightree yesterday.
Atlanta, Ga.-based Brightree develops cloud-based software for home or durable medical equipment for home health and hospice care. Its majority owner was private equity shop Battery, which bought its stake in 2008. Read more
2. Edwards Lifesciences hits all-time high on Sapien 3 study
Shares in Edwards Lifesciences hit an all-time high yesterday after the company reported strong 1-year data for its Sapien 3 replacement heart valve over the weekend.
Results from the Partner II trial from 1,077 intermediate-risk patients showed that the Sapien 3 beat surgical valve replacement across a variety of safety endpoints, Irvine, Calif.-based Edwards said at the American College of Cardiology’s annual meeting April 3. The combined all-cause death & disabling stroke rate was 8.4% for TAVR with Sapien 3 and 16.6% for the surgery arm, according to the study, which was also published in The Lancet. The Sapien 3 device won a nod from the FDA in June 2015 for high-risk patients. Read more
1. Boston Scientific halts EU sales of next-gen Watchman FLX anti-stroke device
Boston Scientific reportedly halted European sales of its the next generation of its anti-stroke device, the Watchman FLX, after receiving reports of device embolization.
Spokeswoman Trish Backes told TCTMD that there were 6 device embolizations in 207 (2.9%) European implantations of the Watchman FLX, an implant that designed to occlude the heart’s left atrial appendage. One of those patients died from complications related to an infection suffered after the device was retrieved. Read more
